Traders should monitor upcoming clinical data readouts and potential achievement of the third $10 million milestone later in 2026. The partnership with Novo Nordisk de-risks development and validates LX9851's potential, supporting upside in Lexicon's valuation despite its small market cap.
Price Chart
Executive Summary
Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX9851, a first-in-class oral obesity candidate discovered by Lexicon. As a result, Lexicon earned a $10 million milestone payment and remains eligible for up to $1 billion in total milestones plus royalties on future sales.
Key Financial Metrics
Key Facts
- Novo Nordisk initiated a Phase 1 study of LX9851, triggering a $10 million milestone payment to Lexicon.
- Lexicon is eligible for up to $1 billion in total upfront and milestone payments, including a third $10 million milestone potentially this year.
- LX9851 is a novel oral non-incretin drug targeting obesity with preclinical data showing enhanced weight loss when combined with semaglutide.
- The Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in 96 individuals with overweight or obesity, with completion expected in Q1 2027.
Financial Impact
$10 million received in 2026, with potential for up to $1 billion in total milestones and tiered royalties on future sales
Risk Factors
- Future milestone payments and royalties depend on successful development and regulatory approval, which are uncertain.
- Competition in the obesity pharmacotherapy space is intensifying with GLP-1-based therapies dominating the market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260282 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Aug 6, 2026 8w ago | Press Release | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.92 $2.22 | ▼ −15.63% | ▼ −13.85% | $1.82 (+5.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.89 $2.25 | ▲ +19.05% | ▲ +17.16% | $1.82 (−3.70%) |
May 6, 2026 21w ago | 8-K | $1.68 $1.85 | ▲ +10.12% | ▲ +6.98% | $1.82 (+8.33%) |
Apr 30, 2026 22w ago | 8-K | $1.63 $2.07 | ▼ −26.99% | ▼ −21.71% | $1.82 (−11.66%) |
Apr 30, 2026 22w ago | Press Release | $1.61 $2.21 | ▲ +37.27% | ▲ +32.30% | $1.82 (+13.04%) |
Mar 24, 2026 27w ago | Press Release | $1.72 $1.82 | ▲ +5.81% | ▼ −3.09% | $1.82 (+5.81%) |
Mar 23, 2026 27w ago | Press Release | $1.64 $1.83 | ▲ +11.59% | ▲ +4.17% | $1.82 (+10.98%) |
Mar 16, 2026 28w ago | DEFA14A | $1.62 $1.86 | ▲ +14.81% | ▲ +10.51% | $1.82 (+12.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access